Laprysta

Lacosamide, the active ingredient in Laprysta, is an anticonvulsant presented as a tablet for oral use. It treats partial‑onset seizures in patients with epilepsy. GNH USA supplies Laprysta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic medication used to manage seizures that originate in a specific part of the brain.

Partial‑onset seizures: Reduces the frequency of focal seizures in patients with epilepsy, with or without secondary generalization. Adjunct therapy for focal seizures: Used in combination with other antiepileptic drugs to improve seizure control when monotherapy is insufficient.

Lacosamide may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions including rash and angioedema - Respiratory depression in susceptible individuals

When prescribing Laprysta, consider the following safety measures. - Renal impairment: Adjust dosing and monitor renal function. - Hepatic impairment: Use with caution and monitor liver enzymes. - Cardiac conduction disorders: Obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: Risk unknown; prescribe only if potential benefit justifies the risk. - Driving and operating machinery: Caution advised due to possible dizziness or visual disturbances. - Store at ambient temperature: Keep below 25°C, retain in original packaging, and protect from moisture.

Laprysta can interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May reduce therapeutic effect. - Concurrent use with other sodium‑channel blockers: May enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Alcohol: May exacerbate dizziness and sedation. - Other antiepileptic drugs (e.g., valproate, levetiracetam): May require dose adjustments. - Oral contraceptives: May experience reduced efficacy; consider alternative contraception.